Biophytis Targets Mobility Restoration in Patients with Obesity
France and Cambridge, Massachusetts--(Newsfile Corp. - April 22, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 therapies. While these treatments are revolutionizing obesity care by delivering significant weight loss, they also induce a concerning...
2025-04-22 1:00 AM EDT
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
France and Cambridge, Massachusetts--(Newsfile Corp. - April 9, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as possible in 2025.Following the recent €2.6 million capital increase announced on March 26, 2025, and promising preclinical results presented at the 15th...
2025-04-09 1:30 AM EDT
Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity
France and Cambridge, Massachusetts--(Newsfile Corp. - March 24, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases, announces new preclinical results for its investigational drug BIO101. These results were presented for the first time last week at...
2025-03-24 2:30 AM EDT
Biophytis Revolutionizes Sarcopenia
France and Cambridge, Massachusetts--(Newsfile Corp. - March 17, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "company"), a clinical-stage biotechnology company specialized in developing therapies for age-related diseases, is excited to announce a world premiere: the publication of the Phase 2 clinical trial SARA-INT in the Journal of Cachexia, Sarcopenia and Muscle (JCSM), the key reference journal for research on sarcopenia.Key BIO101 Attributes from the SARA INT...
2025-03-17 2:00 AM EDT
Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
France and Cambridge, Massachusetts--(Newsfile Corp. - February 25, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking place from March 12 to 14 in Toulouse.The International Conference on Frailty...
2025-02-25 1:00 AM EST
Biophytis Unveils Its Outlook Strategies for 2025
France and Cambridge, Massachusetts--(Newsfile Corp. - February 11, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today unveils its strategic outlook for the year 2025.Biophytis has improved its competitive positioning and fundamentals in recent months, paving the way for accelerated execution of its strategic roadmap: Launch of the OBA clinical development...
2025-02-11 1:00 AM EST
Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference
France and Cambridge, Massachusetts--(Newsfile Corp. - January 27, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the Biomed Forum organized by All Invest Securities on February 4, 2025, in Paris.The Biomed Forum is the annual event dedicated to the healthcare sector, fostering connections between biotech or medtech companies and...
2025-01-27 1:00 AM EST
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China
France and Cambridge, Massachusetts--(Newsfile Corp. - January 21, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the signing of a co-development agreement with AskHelpU, the largest patient association in China for those affected by Amyotrophic lateral sclerosis (ALS).This co-development agreement aims to evaluate the efficacy of BIO101, Biophytis'...
2025-01-21 1:00 AM EST
Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101
France and Cambridge, Massachusetts--(Newsfile Corp. - January 14, 2025) - Biophytis SA (OTC Pink: BPTSY) (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces that it has entered exclusive negotiations with a leading Chinese pharmaceutical company. The purpose of these discussions is to finalize a licensing agreement to co-develop and commercialize BIO101 (20-Hydroxyecdysone) in...
2025-01-14 1:00 AM EST